Population Pharmacokinetics of Vancomycin in Adult Patients with Long Bones’ Fractures

1. Jarkowski A, Forrest A, Sweeney RP et al. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012;18(1):91-6.10.1177/107815521140210721521799Search in Google Scholar

2. Marsot A, Boulamery A, Bruguerolle B et al. Vancomycin: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2012;51(1):1-13.10.2165/11596390-000000000-0000022149255Search in Google Scholar

3. Adane ED, Herald M, Koura F. Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections. Pharmacotherapy. 2015;35(2):127-39.10.1002/phar.153125644478Search in Google Scholar

4. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;6:848-52.10.1128/AAC.32.6.8481722943415206Search in Google Scholar

5. Darko W, Medicis JJ, Smith A et al. Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy. 2003;23(5):643-50.10.1592/phco.23.5.643.3219912741439Search in Google Scholar

6. Lodise TP, Patel N, Lomaestro BM et al. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin Infect Dis. 2009;49(4):507-14.10.1086/60088419586413Search in Google Scholar

7. De Hoog M, Mouton JW, Van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-94.10.1016/j.siny.2004.10.00415701583Search in Google Scholar

8. Purwonugroho TA, Chulavatnatol S, Preechagoon Y et al. Population Pharmacokinetics of Vancomycin in Thai Patients. Scientific World Journal. 2012;2012:762649.10.1100/2012/762649332248122547995Search in Google Scholar

9. Lin WW, Wu W, Jiao Z et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2016;72(1):29-37.10.1007/s00228-015-1952-626423622Search in Google Scholar

10. Stockmann C, Hersh AL, Roberts JK et al. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther. 2015;4(2):187-98.10.1007/s40121-015-0067-9447105625998107Search in Google Scholar

11. Hahn A, Frenck RW Jr, Zou Y et al. Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit. 2015;37(3):413-6.10.1097/FTD.0000000000000153443190525423413Search in Google Scholar

12. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guide. Parts I–VIII ICON Development Solutions.Search in Google Scholar

13. Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokineticpharmacodynamic study: a journal's perspective. Clin Pharmacokinet. 2014;53(2):111-2.10.1007/s40262-013-0114-124327237Search in Google Scholar

14. Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study.Acta Anaesthesiol Scand. 2017;61(6): 627-35.10.1111/aas.12897548505428444760Search in Google Scholar

15. Campassi ML, Gonzalez MC, Masevicius FD et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment. Rev Bras Ter Intensiva. 2014; 26:13-20.10.5935/0103-507X.20140003403188624770684Search in Google Scholar

16. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49: 325–7.10.1086/60087719569969Search in Google Scholar

17. Saugel B, Gramm C, Wagner JY et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014; 29:351-5.10.1016/j.jcrc.2013.12.00724456810Search in Google Scholar

18. Hutschala D, Kinstner C, Skhirdladze K et al. Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versus Intermittent Infusion. Anesthesiology. 2009;111(2): 356-65.10.1097/ALN.0b013e3181a9727219602966Search in Google Scholar

19. Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7(3):136-47.10.1177/2042018816638223489239827293542Search in Google Scholar

20. Nakamura T, Hashimoto Y, Kokuryo T et al. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceutical research.1998;15(5):734-8.10.1023/A:1011971019868Search in Google Scholar

21. Philadelphia, PA: Pfizer; 2012. Zosyn (piperacillin-tazobactam) package insert. https://www.pfizermedicalinformation.com/en-us/zosyn/storage-handling.Search in Google Scholar

22. Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis. 2017;64 (5):666-74.Search in Google Scholar

23. Blevins AM, Lashinsky JN, McCammon C et al. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin/Tazobactam, Cefepime, or Merope nem. Antimicrob Agents Chemother. 2019. pii:AAC.02658-18.10.1128/AAC.02658-18649606430782987Search in Google Scholar

24. Kim T, Kandiah S, Patel M et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC research notes. 2015;8(1):579.10.1186/s13104-015-1518-9460906326476979Search in Google Scholar

25. Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471-9.10.1093/jac/dkv37226568565Search in Google Scholar

26. Sanchez JL, Dominguez AR, Lane JR et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: Comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48: 525–33.10.5414/CPP48525Search in Google Scholar

27. Garaud JJ, Regnier B, Ingleber F et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984;14, Suppl. D, 53-5.10.1093/jac/14.suppl_D.53Search in Google Scholar

28. Rotschafer JC, Crossley K, Zaske DE et al. Pharmacokinetics of Vancomycin: Observations in 28 Patients and Dosage Recommendations. Antimicrob Agents Chemother. 1982;22(3):391-4.10.1128/AAC.22.3.3911837547137982Search in Google Scholar

29. Al-Kofide H, Zaghloul I, Al-Naim L Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010;16(4):245-50.10.1177/107815520935584720015925Search in Google Scholar

30. Moore JN, Healy JR, Thoma BN et al. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane. CPT Pharmacometrics Syst Pharmacol. 2016;5(9): 495-502.10.1002/psp4.12112503642427639260Search in Google Scholar